ICER: Unsubstantiated drug price increases cost US $1.67B in 2020, but overall net increases lower than years past

The Institute for Clinical and Economic Review on Tuesday morning released its latest on “unsupported” drug price increases for seven top treatments, and how even after rebates and other concessions, these increases cost the US health system an additional $1.67 billion, including almost $1.4 billion from AbbVie’s Humira alone.